Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.78 - $24.00
Previous CloseN/A
Volume29.05K
Average Volume (3M)85.96K
Market Cap
$162.66M
Enterprise Value$151.46M
Total Cash (Recent Filing)-$337.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 28, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding10,807,726
10 Day Avg. Volume95,041
30 Day Avg. Volume85,958
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit57.50
Enterprise Value/Ebitda-5.42
Forecast
1Y Price Target
$30.00Price Target Upside83.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Mediwound News
PremiumCompany Announcements
MediWound Announces 2025 Annual General Meeting and Key Agenda Items
PremiumCompany Announcements
MediWound’s Earnings Call: Progress Amid Financial Challenges
---
Bulls Say, Bears Say
Bulls Say
Funding And Financial SupportMediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx in the DFU indication.
Market ExpansionNexoBrid is launching in three new markets – the US, Japan and India – and should benefit from a recently formed partnership with PolyMedics Innovations for the product's promotion in five European countries.
Partnerships And CollaborationsMediwound has secured an additional collaboration for its DFU study, with Kerecis joining to contribute its MariGen Fish-Skin graft, representing additional validation for the potential of EscharEx.
Bears Say
Manufacturing CapacityGlobal demand for NexoBrid currently exceeds MDWD's manufacturing capacity by roughly threefold, a dynamic that will ease over the course of this year as manufacturing capacity ramps.
Regulatory DelaysNexoBrid guidance tightened towards lower end, reflecting adjusted timelines for EU approval of the manufacturing facility.
Supply LimitationsNexoBrid sales are limited only by supply, as demand for the product continues to exceed supply.
---
Ownership Overview
―
Insiders
1.87% Mutual Funds
28.39% Other Institutional Investors
65.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.78 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $162.66M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is May 28, 2025 which is in 45 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Mar 19, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.576 by $0.216.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.65.
How many shares outstanding does Mediwound have?
Mediwound has 10,807,726 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.576. Following the earnings report the stock price went down -5.138%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
---
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (83.26% Upside)
$30.00 (83.26% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 252.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.28%
12-Months-Change
Fundamentals
Return on Equity
-96.33%
Trailing 12-Months
Asset Growth
10.59%
Trailing 12-Months
Company Description
Mediwound
Mediwound Ltd. is a biopharmaceutical company operating in the healthcare sector, focusing on the development, manufacturing, and commercialization of novel therapeutics for tissue repair and regeneration. The company's core products include innovative enzyme-based solutions designed to treat severe burns, chronic wounds, and other hard-to-heal injuries. Mediwound's flagship product, NexoBrid, is used for the removal of eschar in adults with deep partial- and full-thickness thermal burns.
---
MDWD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical and commercial progress, particularly with EscharEx and NexoBrid, along with strategic collaborations and a strong financial backing. However, the increased operating and net losses, along with a decline in gross margin, suggest financial challenges. The positive advancements in products and strategic partnerships indicate a promising outlook despite these financial hurdles.Read More>---
MDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(83.26% Upside)
Technical Analysis
Best Analysts Covering MDWD
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+35.05%
reiterated a buy rating 24 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +35.05% per trade.
---